Payment overview · 2025
General Payments
$818.49
29 reported records · 13 companies
Healthcare provider profile · identity verified
John Nguyen, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · CYPRESS, TX · NPI 1831125319
Verified facts
What the public records show
CMS Open Payments records show John Nguyen, M.D. received $818.49 in general payments during 2025 across 29 reported records.
Boston Scientific Corporation accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Edarbi, Eliquis.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Edarbi by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 307 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 307 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $177.82 | 21.7% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $112.55 | 13.8% | 6 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $106.36 | 13.0% | 2 | 2025 |
| REVANCE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $97.42 | 11.9% | 1 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $95.65 | 11.7% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$58.87 | 7.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $49.79 | 6.1% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $29.04 | 3.5% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $25.93 | 3.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.24 | 2.1% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $17.08 | 2.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.60 | 2.0% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.14 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $818.49 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DAXXIFY Normalized: daxxify |
Drug | REVANCE THERAPEUTICS, INC. | $97.42 | 1 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $95.65 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $92.86 | 5 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $82.54 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $74.63 | 2 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $42.02 | 1 | 2025 |
Source payment records
|
|||||
| RESONATE EL ICD VR Normalized: resonate el icd vr |
Device | Boston Scientific Corporation | $40.87 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.86 | 2 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $29.04 | 2 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $27.31 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $25.93 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $25.93 | 1 | 2025 |
Source payment records
|
|||||
| ALPHAVAC Normalized: alphavac |
Device | AngioDynamics, Inc. | $23.82 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| LINQ II Normalized: linq ii |
Device | Medtronic, Inc. | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| LATITUDE Communicator Power Supply Normalized: latitude communicator power supply |
Device | Boston Scientific Corporation | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $14.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| EDARBI edarbi |
2025 | Edarbi | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 307 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
307 | 74 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
307 | 74 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 352 | 104 |
| Eliquis | Apixaban | 307 | 74 |
| Atorvastatin Calcium | Atorvastatin Calcium | 302 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 275 | 88 |
| Xarelto | Rivaroxaban | 231 | 50 |
| Carvedilol | Carvedilol | 227 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 212 | 73 |
| Clopidogrel | Clopidogrel Bisulfate | 208 | 67 |
| Furosemide | Furosemide | 191 | 76 |
| Amiodarone Hcl | Amiodarone Hcl | 148 | 45 |
| Nifedipine Er | Nifedipine | 136 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 123 | 47 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 118 | 35 |
| Ranolazine Er | Ranolazine | 118 | 32 |
| Lisinopril | Lisinopril | 96 | 32 |
| Spironolactone | Spironolactone | 96 | 32 |
| Warfarin Sodium | Warfarin Sodium | 96 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 88 | 33 |
| Potassium Chloride | Potassium Chloride | 75 | 30 |
| Sotalol | Sotalol Hcl | 74 | 21 |
| Clonidine Hcl | Clonidine Hcl | 72 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 71 | 23 |
| Bumetanide | Bumetanide | 70 | 16 |
| Flecainide Acetate | Flecainide Acetate | 70 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | 20 |
| Entresto | Sacubitril/Valsartan | 64 | 22 |
| Digoxin | Digoxin | 61 | 16 |
| Simvastatin | Simvastatin | 59 | 20 |
| Nitroglycerin | Nitroglycerin | 55 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 52 | 20 |
| Ezetimibe | Ezetimibe | 46 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 31 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | 12 |
| Brilinta | Ticagrelor | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Valsartan | Valsartan | 27 | 11 |
| Atenolol | Atenolol | 26 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Sotalol Af | Sotalol Hcl | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Klor-Con | Potassium Chloride | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Praluent Pen | Alirocumab | 14 | suppressed |
| Edarbi | Azilsartan Medoxomil | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $818.49 · 29 records | Boston Scientific Corporation | ALPHAVAC, AREXVY, AURYON LASER SYSTEM 100-120 VAC, BodyGuardian, CAMZYOS, CARDIOMEMS, DAXXIFY, EDARBI, ELIQUIS, General - Therapies, LATITUDE Communicator Power Supply, LINQ II, MICRA, OPSUMIT, PAXLOVID, REPATHA, RESONATE EL ICD VR, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, UPTRAVI, VYNDAQEL, WATCHMAN FLX | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Edarbi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Azurity Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error